GlassScriptPhysician profile
Michael B Sternthal
NPI 1992781876
$8,748.79
in general payments reported to CMS, 2019-2025
37 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $520 · 2021: $1,399 · 2022: $1,752 · 2023: $1,392 · 2024: $1,317 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,953.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,025.97 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Janssen Biotech, INC. | $1,143.71 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $770.34 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $550.00 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $451.89 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $405.85 | 2019-2025 | |
| Genzyme Corporation | $393.86 | 2022-2025 | |
| Redhill Biopharma INC. | $191.90 | 2020-2023 | Talicia |
| Celgene Corporation | $191.07 | 2022-2024 | Zeposia |
| Pfizer INC. | $154.44 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $146.61 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $139.79 | 2022-2025 | Dupixent |
| Shire North American Group INC | $124.68 | 2019 | |
| Intercept Pharmaceuticals, INC. | $88.74 | 2020-2023 | Ocaliva |
| Qol Medical, LLC | $88.47 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $85.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $69.96 | 2021-2024 | Pancreaze |
| Lilly USA, LLC | $67.85 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $67.78 | 2020-2025 | |
| Ferring Pharmaceuticals INC. | $65.99 | 2020-2023 | Rebyota |
| Allergan, INC. | $60.42 | 2019 | |
| Braintree Laboratories, INC. | $47.51 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $45.78 | 2019-2023 | Kristalose |
| Merck Sharp & Dohme LLC | $44.20 | 2019-2021 | |
| Amgen INC. | $39.19 | 2021-2023 | Amjevita |
| Pharmacosmos Therapeutics INC. | $37.00 | 2022-2023 | Monoferric |
| Aimmune Therapeutics, INC. | $36.68 | 2024-2025 | Zenpep |
| Alfasigma USA, INC. | $34.23 | 2021 | |
| Cook Medical LLC | $25.51 | 2020 | |
| Mylan Institutional INC. | $22.45 | 2023 | Hulio |
| Shionogi INC | $22.23 | 2019 | |
| Fresenius Kabi USA, LLC | $21.93 | 2024 | Idacio |
| Organon LLC | $20.53 | 2021-2023 | Renflexis |
| Phathom Pharmaceuticals, INC. | $19.70 | 2024 | Voquezna |
| Vibrant Gastro, INC. | $19.08 | 2024 | Vibrant Starter Kit |
| Ucb, INC. | $16.45 | 2021 | |
| Evoke Pharma, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sternthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.